Key result
High baseline plasma BNP levels (≥170 pg/mL) were significantly associated with an increased risk of thromboembolic events (HR 3.86) in Japanese patients with nonvalvular atrial fibrillation.
Why the study?
Does high baseline BNP level predict thromboembolic events and death in patients with nonvalvular atrial fibrillation?
Population
1,013 Japanese adults with nonvalvular atrial fibrillation from the Hokuriku-plus AF Registry, mean age 72.8…
Comparison
High baseline B-type natriuretic peptide level vs Low baseline B-type natriuretic peptide level
Design
Cohort
Follow-up
median 751 days
Authors
Loading...
May aid thromboembolic risk stratification beyond CHA2DS2-VASc in nonvalvular AF; leaves open prospective validation before practice change.
Cohort (n=1,013)
Yes
Does high baseline BNP level predict thromboembolic events and death in patients with nonvalvular atrial fibrillation?
Hazard Ratio: 3.86 (95% CI 1.83–8.67)
Absolute Event Rate: 3.2% vs 0.7%
p-value: p=0.0003
Elevated baseline BNP levels independently predict thromboembolic events and death in patients with nonvalvular atrial fibrillation, and adding BNP to the CHA2DS2-VASc score improves risk stratification.
Hayashi et al. (2018) conducted a cohort in Nonvalvular Atrial Fibrillation (n=1,013). High B-type natriuretic peptide (BNP) level (≥170 pg/mL) vs. Low BNP level (<170 pg/mL) was evaluated on Thromboembolic events (TE) (HR 3.86, 95% CI 1.83-8.67, p=0.0003). High baseline plasma BNP levels (≥170 pg/mL) were significantly associated with an increased risk of thromboembolic events (HR 3.86) in Japanese patients with nonvalvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: